multiple sclerosis. Demyelinating diseases of the central nervous system
Conditions
Interventions
Treatment - Drugs
Sponsors
Arak University of Medical Science,Office of Vice Chancellor for Research
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: inclusion criteria: age 18–50 years? ?clinically definitive relapsing remitting MS((according to the 2005 revised McDonald criteria)confirmed by a neurologist ? Additional inclusion criteria were an Expanded disability Status Score (EDSS) of less or equal to 5.5 ? exclusion criteria: progressive forms of multiple sclerosis ? an onset of relapse or receipt of any glucocorticoid treatment during trial period ? use of immunomodulatory, immunosuppressive, IVIg or plasmapherasis or antidepressant drugs in the previous 6 months? the use of corticosteroids in the previous 8 weeks ? depression defined as a score of 19 or higher on Beck’s Depression Inventory II ?contraindication to MRI ? other neurological or systemic disorder that would interfere with the assessments ? pregnancy or unwillingness to use acceptable birth control. severe suicidality including ideation, plan, and intentclinically significant ? unstable medical or surgical conditions that would preclude safe and complete participation in the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EDSS (Expanded Disability Status Scale). Timepoint: WEEK 0 AND24. Method of measurement: evaluate by neurologist.;The cumulative number of lesions on different phases of brain MRI. Timepoint: WEEK 0 AND24. Method of measurement: counting the plaques by researchers. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShayan Amjadi
Students Research Committe , Medicine faculty , Aarak University of Medical Science
Outcome results
None listed